🟢 Veru is trading 5.5% up in pre-market after Oppenheimer reiterated its Outperform rating

Veru is trading 5.48% up in pre-market at $2.31; Oppenheimer’s reiterated Outperform rating is a plausible company-specific catalyst. - Investing.com reported shares rose 1.8% in after-hours trading after Oppenheimer reiterated its Outperform rating and $24 price target, citing interim data from the Phase 2b PLATEAU obesity-drug trial, expected next quarter. - Shares closed at $2.19 on October 13, down 8.94% that session. No trading-volume figure was available, and broader-market context does not establish a cause.